Study Evaluating Multiple Doses Of GSI-953 Within The Elderly Population

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy

In brief

To assess the safety and tolerability of ascending, multiple, oral doses of GSI-953 in healthy elderly subjects.

Key facts

Study ID

NCT00547560

Run by

Wyeth is now a wholly owned subsidiary of Pfizer

People needed

49

Starts

2007-08-01

Expected to finish

2009-10-01

Last updated by the study team

2011-04-04

Who can join

Age: 65 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Men or women, greater than or equal to 65 years of age.
• Women of nonchildbearing potential (WONCP) may be included if they are either surgically sterile (hysterectomy and/or oophorectomy) or postmenopausal for greater than or equal to 1 year (with FSH greater than or equal to 38 mIU/mL) and must have a negative pregnancy test result within 48 hours before administration of test article. Women who are surgically sterile must provide documentation of the procedure by an operative report or by ultrasound.
• Body mass index (BMI) in the range of 18.0 to 30.0 kg/m2 and body weight >50 kg.

You may not qualify if…

• n/a

Where it is running

• Pfizer Investigational Site — Miami, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.